<p>The clearance of amiodarone after intravenous administration in patients with ventricular fibrillation and ventricular tachycardia ranged from 220 to 440 ml/hr/kg in one clinically study.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CORDARONE (amiodarone HCl) tablets" href="#reference-L3561">18</a></sup> Another study determined that the total body clearance of amiodarone varies from 0.10 to 0.77 L/min after one intravenous dose.<sup class="text-reference-group"><a class="reference-popover-link" data-content="Latini R, Tognoni G, Kates RE: Clinical pharmacokinetics of amiodarone. Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002. (PubMed ID 6370540)" href="#reference-A36817">4</a></sup> Renal impairment does not appear to affect the clearance of amiodarone, but hepatic impairment may reduce clearance. Patients with liver cirrhosis exhibited significantly lower Cmax and mean amiodarone concentration for DEA, but not for amiodarone. Severe left ventricular dysfunction prolongs the half-life of DEA.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CORDARONE (amiodarone HCl) tablets" href="#reference-L3561">18</a></sup></p><p>A note on monitoring </p><p>No guidelines have been developed for adjusting the dose of amiodarone in renal, hepatic, or cardiac abnormalities. In patients on chronic amiodarone treatment, close clinical monitoring is advisable, especially for elderly patients and those with severe left ventricular dysfunction.<sup class="text-reference-group"><a class="reference-popover-link" data-content="FDA Approved Drug Products: CORDARONE (amiodarone HCl) tablets" href="#reference-L3561">18</a></sup></p>